Bulent Cetin

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

Journal: Journal of clinical medicine

Published: June 24, 2026

Facing death: the last drawings of a woman with breast cancer at the end of life.

Journal: NPJ breast cancer

Published: January 23, 2026

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 06, 2026

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 06, 2026

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.

Journal: Current treatment options in oncology

Published: October 19, 2025

Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer.

Journal: Frontiers in oncology

Published: October 15, 2025

First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.

Journal: Cancer chemotherapy and pharmacology

Published: August 26, 2025

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Journal: Clinical breast cancer

Published: June 29, 2024

Prognostic value of computed tomography associated body composition measurement changes in metastatic colorectal cancer patients.

Journal: Acta radiologica (Stockholm, Sweden : 1987)

Published: September 04, 2023

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

Journal: The New England journal of medicine

Published: August 30, 2023

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Journal: The oncologist

Published: August 04, 2023

Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.

Journal: Immunotherapy

Published: June 09, 2023

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

Facing death: the last drawings of a woman with breast cancer at the end of life.

Facing death: the last drawings of a woman with breast cancer at the end of life.

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.

Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer.

Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer.

First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.

First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Prognostic value of computed tomography associated body composition measurement changes in metastatic colorectal cancer patients.

Prognostic value of computed tomography associated body composition measurement changes in metastatic colorectal cancer patients.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.

Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.